Gamma-secretase as a pharmacological target in Alzheimer disease research: When, why and how?

Current Pharmaceutical Design

Volumn 12, Issue 33, 2006, Pages 4313-4335

  Ziani Cherif, Chewki ^a   Mostefa Kara, Bachir ^a   Brixi Gormat, Fatima Z ^a  

^a UNIVERSITY OF TLEMCEN   (Algeria)

Author keywords

secretase; secretase inhibitors; Alzheimer disease; Amyloid ; Amyloid precusor protein; Non steroidal anti inflammatory drugs; Presenilins

Indexed keywords

[1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; ASPARTIC PROTEINASE; BAFILOMYCIN A1; BENZODIAZEPINE DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA SECRETASE; BMS 289948; BMS 299897; CALPASTATIN; CALPECTIN; CATHEPSIN D; CURCUMIN; FLURBIPROFEN; GAMMA SECRETASE INHIBITOR; GLYCOSAMINOGLYCAN; IBUPROFEN; INDOMETACIN; NICASTRIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PLACEBO; PRESENILIN 1; PRESENILIN 2; SIGNAL PEPTIDE; SULINDAC SULFIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CHEMICAL STRUCTURE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG DESIGN; DRUG POTENCY; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SENILE PLAQUE; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ENZYME INHIBITORS; HUMANS;

EID: 33750846768     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778792994     Document Type: Review

References (231)

1. Cummings JL, Cole G. Alzheimer Disease. JAMA 2002; 287: 2335-8.
2. Villareal DT, Morris JC. The diagnosis of Alzheimer's disease. Alz Dis Rev 1998; 3: 142-52.
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
4. Selkoe DJ, Lansbury PJ Jr. Biochemistry of Alzheimer's disease and prion diseases. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD 6th Ed, Basic Neurochemistry, Molecular, Cellular and Medical Aspects. Philadelphia, Lipincott-Raven. 1999; 949-68.
5. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-42.
6. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: High avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer Disease. Proc Natl Acad Sci USA 1993; 90: 1977-8.
7. For recent articles on the APOE, see J. Mol Neurosci 2004; 23; issue 3.
8. Poirier J. Apoliprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann NY Acad Sci 2000; 924: 81-90.
9. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease. Nat Genet 1994; 7: 180-4.
10. Guo A, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000; 54: 1316-23.
11. Clarke R, Smith AD, Jobst KA, Jobst KA, Refsum H, Sutton L, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-55.
12. Evans DA, Hebert LE, Beckett LA, Scherr PA, Albert MS, Chown MJ, et al. Education and other measures of socioeconomic status and risk of incident Alzheimer in a defined population of older persons. Arch Neurol 1997; 54: 1399-1405.
13. Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer's disease. Ann Neurol 1993; 33: 258-66.
14. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, et al. Rates and risk factors for dementia and Alzheimer's disease. Neurology 1999; 52: 78-84.
15. Kalmijn S, Launer LJ, Ott A, Witteman JCM, Hofman A, Breteler MMB. Dietary fat intake and the risk factors for dementia and Alzheimer's disease. Ann Neurol 1997; 42: 776-82.
16. Orgogozo J-M, Dartigues J-F, Lafont S, Letenneur L, Commenges D, Salamon R, et al. Wine consumption and dementia in the elderly. Rev Neurol (Paris) 1997; 3: 185-92.
17. Kramer AF, Colcombe SJ, McAuley E, Eriksen KI, Scalf P, Jerome GJ, et al. Enhancing brain and cognitive function of older adults through fitness training. J Mol Neurosci 2003; 20: 213-22.
18. Folstein MF, Folstein SE, McHugh PR. Minimental State. J Psychiatr Res; 1975; 12: 189-198.
19. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST, et al. Practice parameter: early detection of dementia. Neurology 2001; 56: 1133-42.
20. Wang Y, Klunk E, Debnath ML, Huang G-F, Daniel P, Shao L, Mathis CA. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J Mol Neurosci 2004; 24: 55-62.
21. Kung M-P, Zhuang Z-P, Hou C, Kung HF. Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging. J Mol Neurosci 2004; 24: 49-54.
22. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburg Compound-B. Ann Neurol 2004; 55: 306-19.
23. Small GW. Brain-imaging surrogate markers for detection and prevention of age-related memory loss. J Mol Neurosci 2002; 19: 17-22.
24. Galasko D. Biological markers and the treatment of Alzheimer's disease. J Mol Neurosci 2001; 17: 119-25.
25. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. J Amer Soc Exper NeuroTherapeutics 2004; 1: 213-225.
26. Grundman M, Sencakova D, Jack CA, Petersen RC, Kim HT, Schultz A, et al. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 2002; 19: 23-28.
27. Helpern JA, Jensen J, Lee S-P, falangola MF. Quantitative MRI assessment of Alzheimer's disease. J Mol Neurosci 2004; 24: 45-48.
28. 1H MRI detection of amyloid β plaques in vivo. Nat Neurosci 2005; 8: 527-33.
29. Evanko D. Imaging Alzheimer disease: seeing the unseeable. Nat Methods 2005; 2: 481.
30. Dickson DW. Pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997; 56: 321-39.
31. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084-89.
32. For recent articles on neurofibrillary tangles as a target for AD, see J Mol Neurosci 2002; 19: Issue 3.
33. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991; 353: 844-6.
34. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6.
35. Murrell J, Farlow M, Ghetti B, Benson M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991; 254: 97-9.
36. Sherrington R, Roaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-60.
37. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-7.
38. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998; 282: 1914-7.
39. Spillantini MG, Murell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998; 95: 7737-41.
40. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-5.
41. Gotz J, Chen F, Van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491-5.
42. Terry RD, Hansen LA, DeTeresa R, Davies P, Tobias H, Katzman R. Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropath Exp Neurol 1987; 46: 262-268.
43. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 298: 962-4.
44. Hardy J. The relationship between amyloid and tau. J Mol Neurosci 2003; 20: 203-6.
45. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004; 61: 378-84.
46. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Cryns VL, et al. Caspace cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA 2003; 100: 10032-37.
47. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Comm 1984; 122: 1131-5.
48. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Comm 1984; 120: 885-90.
49. Gorevic P, Goni F, Pons-Estel B, Alvarez F, Peress R, Frangione B. Isolation and partial characterization of neurofibrillary tangles and amyloid plaque cores in Alzheimer's disease: immunohistological studies. J Neuropathol Exp Neurol 1986; 45: 647-664.
50. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-49.
51. Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. Isolation of low-molecular weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem 1986; 146: 1820-34.
52. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-36.
53. Selkoe DJ. Cell biology of the amyloid-β protein precursor and the mecanism of Alzheimer's disease. Annu Rev Cell Biol 1994; 10: 373-403.
54. Bayer TA, Wirths O, Majtényi K, Hartmann T, Multhaup G, Beyreuther K, et al. Key factors in Alzheimer's disease: β-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 2001; 11: 1-11.
55. Clippingdale AB, Wade JD, Barrow CJ. The amyloid-β peptide and its role in Alzheimer's disease. J Pept Sci 2001; 7: 227-49.
56. Wisniewski T, Ghiso J, Frangione B. Biology of Aβ amyloid in Alzheimer's disease. Neurobiol Dis 1997; 4: 313-28.
57. Koo EH, Sisodia SS, Cork LC, Unterbeck A, Bayney RM, Price DL. Differential expression of amyloid precursor protein mRNAs in cases of Alzheimer's disease and in aged nonhuman primates. Neuron 1990; 4: 97-104.
58. Kar S, Slowikowski SPM, Westaway D, Mount HTJ. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 2004; 29: 427-41.
59. Wasco W, Bupp K, Magendantz M, Guselle JF, Tanzi RE, Solomon F. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor. Proc Natl Acad Sci USA 1992; 89: 10758-62.
60. Slunt HH, Thinakaran G, Von Koch C, Lo ACY, Tanzi RE, Sisodia SS. Expression of a ubiquitous, cross-reactive homologue of the mouse β-amyloid precursor protein (APP). J Biol Chem 1994; 269: 2637-44.
61. Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 2000; 20: 7951-63.
62. Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJS, Hopkins R, Smith DW, et al. β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995; 81: 525-31.
63. Perez RG, Zheng H, Van Der Ploeg LH, Koo EH. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci 1997; 17: 9407-14.
64. Chan SL, Furukawa K, Mattson MP. Presenilins and APP in neuritic and synaptic plasticity: implications for the pathogenesis of Alzheimer's disease. Neuromolec Med 2002; 2: 167-96.
65. Koudinov AR, Berezov TT. Alzheimer's amyloid-beta (A beta) is an essential synaptic protein, not neurotoxic junk. Acta Neurobio Exp (Wars) 2004; 64: 71-9.
66. Schellenberg GD, Bird TD, Wijsman EM, Orr HT Anderson L, Nemens E, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258: 668-71.
67. Selkoe DJ. Alzheimer Disease: Mechanistic understanding predicts novel therapies. Ann Intern Med 2004; 140: 627-638.
68. For complete list of mutations and more, see htp://www.alzforum.org/ members/resources/pres_mutations/index.html.
69. Tandon A, Fraser P. The presenilins. Genome Biol 2002; 3: 3014.1-3014.9.
70. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 1996; 17: 181-90.
71. Yu G, Chen F, Levesque G, Nishimura M, Zhang D-M, Levesque L, et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J Biol Chem 1998; 273: 16470-75.
72. Rogaev El, Sherrington R, Wu C, Levesque G, Liang Y, Rogaeva EA, et al. Analysis of the 5′ sequence, genomic structure, and alternative splicing of the presenilin 1 (PSEN1) associated with early onset Alzheimer disease. Genomics 1997; 40: 415-424.
73. Thinakaran G. Metabolism of Presenilins. J Mol Neurosci 2001; 17: 183-92.
74. Naruse S, Thinakaran G, Luo J-J, Kusiak JW, Tomita T, Iwatsubo T, et al. Effetcs of PS1 deficiency on membrane protein trafficking in neurons. Neuron 1998; 21: 1213-21.
75. Leem JY, Vijayan S, Han P, Cai D, Machura M, Lopes KO, et al. Presenilin 1 is required for maturation and cell surface accumulation of nicastrin. J Biol Chem 2002; 277: 19236-40.
76. Mattson, MP, Chan SL, Camandola S. Presenilin mutations and calcium signaling defects in the nervous and immune systems. Bioessays 2001; 23: 733-44.
77. Thinakaran G, Parent A.T. Identification of the role of presenilins beyond Alzheimer's disease. Pharm Res 2004; 50: 411-18.
78. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-70.
79. Thinakaran G. The role of presenilins in Alzheimer's disease. J Clin Invest 1999; 104: 1321-27.
80. De Strooper, B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387-90.
81. Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2000; 2: 461-2.
82. Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner BA. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat Cell Biol 2000; 2: 463-5.
83. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 1999; 96: 11872-77.
84. Ponting CP, Hutton M, Nyborg A, Baker M, Jansen K, Golde TE. Identification of a novel family of presenilin homologues. Hum Mol Gen 2002; 11: 1037-44.
85. Martoglio B, Golde TE. Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs. Hum Mol Gen 2003; 12: R201-6.
86. Virchow R. Zur cellulosefrage. Virchows Arch Pathol. Anat Physiol 1854; 6: 416-26.
87. Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J Clin Invest 2005; 115: 1121-29.
88. Schenk DB, Rydel RE, May P, Littlé S, Panetta J, Lieberburg I, Sinha S. Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease. J Med Chem 1995; 38: 4141-54.
89. Glenner GG, Terry WD. Characterization of amyloid. Annu Rev Med 1974; 25: 131-135.
90. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family as amyloid precursor protein alpha-secretases. J Neurosci Res 2003; 74: 342-52.
91. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Fahrenholz F, et al. A disintegrin-metalloprotease prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004; 113: 1456-64.
92. Lichtenthaler SF, Haass C. Amyloid at the cutting edge: activation of α-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 2004; 113: 1384-1387.
93. Wei W, Norton DD, Wang X, Kusiak JW. Aβ17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 2002; 125: 2036-2043.
94. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tan J. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc Natl Acad Sci USA 2000; 97: 1456-60.
95. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al. BACE1 is the major β-secretase for the generation of Aβ peptides by neurons. Nat Neurosci 2001; 4: 233-34.
96. Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, Haass C, et al. Identification of a β-secretase activity, which truncates amyloid β-peptide after its presenilin-dependant generation. J Biol Chem 2003; 278: 5531-38.
97. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene regulation and DNA damage in the ageing human brain. Nature 2004; 429: 883-91.
98. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001; 32: 177-80.
99. Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM. Neurovascular Pathways and Amyloid β-peptide. Brain Pathol 2005; 15: 78-83.
100. Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 1996; 17: 921-33.
101. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid betapeptide in the brain cognitive decline. JAMA 2000; 283: 1571-7.
102. Younkin SG. Evidence that Abeta 42 is the real culprit in Alzheimer disease. Ann Neurol 1995; 37: 287-88.
103. Golde TE. Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest 2003; 111: 11-18.
104. Golde TE. The Aβ hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol 2005; 15: 84-87.
105. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000; 924: 17-25.
106. Michaelis ML. Drugs targeting Alzheimer's disease: some things old and some things new. J Pharmacol Exp Ther 2003; 304: 897-904.
107. Cuello CA. Intracellular and extracellular Aβ, a tale of two neuropathologies. Brain Pathol 2005; 15: 66-71.
108. Knops J. Suomensaari S, Lee M, McConlogue L, Seubert P, Sinha S. Cell-type and amyloid precursor-type specific inhibition of Aβ release by bafilomycin A1, a selective inhibitor or Vacuolar ATPases. J Biol Chem 1995; 270: 2419-22.
109. Haass C, Capell A, Citron M, Teplow D.B, Selkoe DJ. The Vacuolar H+-ATPase inhibitor bafilomycin A1 differentially affects proteolytic precessing of mutant and wild type β-amyloid precursor protein. J Biol Chem 1995; 270: 6186-92.
110. Higaki J, Quon D, Zhong Z, Cordell B. Inhibition of β-amyloid formation identifying proteolytic precursors and subcellular site of catabolism. Neuron 1995; 14: 651-59.
111. Klafki HW, Abramoswski D, Swoboda R, Paganetti PA, Staufenbiel M. The carboxy termini of β-amyloid peptides 1-40 and 1-42 are generated by distinct γ-secretase activities. J Biol Chem 1996; 271: 28655-28659.
112. Kopan R, Schroeter EH, Weintraub H, Nye JS. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci USA 1996; 93: 1683-88.
113. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Evidence that the 42- and 40-amino acids of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 1996; 93: 13170-75.
114. Zhang L, Song L, Parker EM. Calpain inhibitor I increases β-amyloid peptide production by inhibiting the degradation of the substrate of γ-secretase. Evidence that substrate availability limits β-amyloid peptide production. J Biol Chem 1999; 274: 8966-72.
115. Durkin JT, Murthy S, Husten EJ, Trusko SP, Savage MJ, Rotella DP, et al. Rank-order of potencies for inhibition of the secretion of Aβ40 and Aβ42 suggests that both are generated by a single γ-secretase. J Biol Chem 1999; 274: 20499-504.
116. Higaki JN, Chakravarty S, Bryant CM, Cowart LR, Harden P, Scardina JM, et al. A combinatorial approach to the identification of dipeptide aldehyde inhibitors of beta-amyloid production. J Med Chem 1999; 42: 3889-98.
117. Kokubu T, Hiwada K, Sato Y, Iwata T, Imamura Y, Matsueda R, et al. Highly potent and specific inhibitors of human renin. Biochem Biophys Res Comm 1984; 118: 929-33.
118. Sarubbi E, Seneci PF, Angelastro MR, Peet NP, Denaro M, Islam K. Peptide aldehydes as inhibitors of HIV protease. FEBS Lett 1993; 319: 253-6.
119. Kurinov IV, Harrison RW. Two crystal structures of the leupeptintrypsin complex. Protein Sci 1996; 5: 752-8.
120. Wolfe MS, Citron M, Diehl TS, Xia W, Donkor IO, Selkoe DJ. A substrate-based difluoro ketone selectively inhibits Alzheimer's γ-secretase activity. J Med Chem 1998; 41: 6-9.
121. Thaisrivongs S, Pals DT, Kati WM, Turner SR, Thomasco LM, Watt W. Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues. J Med Chem 1986; 29: 2080-7.
122. Veerapandian B, Cooper JB, Sali A, Blundell TL, Rosati RL, Dominy BW, et al. Direct observation by X-Ray analysis of the tetrahedral "intermediate" of aspartic proteinases. Protein Sci 1992; 1: 322-8.
123. James MN, Sielecki AR, Hayakawa K, Gelb MH. Crystallographic analysis of transistion state mimics bound to penicilopepsin: difluorostatine- and difluorostatone-containing peptides. Biochemistry 1992; 31: 3872-86.
124. Silva AM, Cachau RE, Sham HL, Erickson JW. Inhibition and catalytic mecanism of HIV-1 aspartic protease. J Biol Chem 1996; 255: 321-46.
125. Wagner SL, Munoz B. Modulation of amyloid β protein precursor processing as a means of retarding progression of Alzheimer's disease. J Clin Invest 1999; 104: 1329-32.
126. Sinha S, Lieberburg I. Cellular mecanisms of β-amyloid production and secretion. Proc Natl Acad Sci USA 1999; 96: 11049-53.
127. Wolfe MS, Xia W, Moore CL, Leatherwood DD, Ostaszewski B, Rahmati T, et al. Peptidomimetic probes and molecular modeling suggest that Alzheimer's γ-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry 1999; 38: 4720-27.
128. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 1999; 398: 513-7.
129. Moore CL, Leatherwood DD, Diehl TS, Selkoe DJ, Wolfe MS. Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's γ-secretase: implications for inhibitor design. J Med Chem 2000; 43: 3434-42.
130. Wolfe MS. Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem 2001; 44: 2039-60.
131. Yu G, Chen F, Nishimura M, Steiner H, Tandon A, Kawarai T, et al. Mutation of conserved aspartates affect mutation of both aspartate-mutant and endogenous presenilin1 and presenilin 2 complexes. J Biol Chem 2000; 275: 27348-53.
132. Steiner H, Romig H, Pesold B, Philipp U, Baader M, Citron M, et al. Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis. Biochemistry 1999; 38: 14600-5.
133. Leimer U, Lun K, Romig H, Walter J, Grünberg J, Brand M, et al. Zebrafish (Danio rerio) presenilin promotes aberrant amyloid betapeptide production and requires a critical aspartate residue for its function in amyloidogenesis. Biochemistry 1999; 38: 13602-9.
134. Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ. The transmembrane aspartates in presenilin 1 and 2 are obligatory for γ-secretase activity and amyloid β-protein generation. J Biol Chem 2000; 275: 3173-8.
135. Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, et al. A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem 1999; 274: 28669-73.
136. Xia X, Wang P, Sun X, Soriano S, Shum W-K, Yamagushi H, et al. The aspartate-257 of presenilin 1 is indispensable for mouse development and production of β-amyloid peptides through β-cateninindependent mechanisms. Proc Natl Acad Sci USA 2002; 99: 8760-65.
137. Steiner H, Kostka M, Romig H, Basset G, Pesold B, Hardy J, et al. Glycin 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat Cell Biol 2000; 2: 848-51.
138. Xia W, Ray WJ, Ostaszewski BL, Rahmati T, Kimberly WT, Wolfe MS, et al. Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid β-protein generation. Proc Natl Acad Sci USA 2000; 97: 9299-304.
139. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Wolfe MS, et al. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat Cell Biol 2000; 2: 428-434.
140. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid-β protein precursor γ-secretase activity. Biochemistry 2000; 39: 8698-704.
141. Li Y-M, Lai M-T, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, et al. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA 2000; 97: 6138-43.
142. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr, et al. Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J Biol Chem 2000; 275: 34086-91.
143. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. Functional gamma-secretase inhibitors reduce betaamyloid peptide levels in brain. J Neurochem 2001; 76: 173-81.
144. Quéléver G, Kraus JL, Kachidian P, Melon C, Garino C, Laras Y, et al. Enhanced delivery of γ-secretase inhibitor DAPT into the brain via an ascorbic acid mediated strategy. Org Biomol Chem 2005; 3: 2450-57.
145. McLendon C, Xin T, Ziani-Cherif C, Golde TE, Murphy MP, Findlay KA, et al. Cell-free assays for γ-secretase activity. FASEB J 2000; 14: 2383-86.
146. Piper SC, Amtul Z, Galiñanes-Garcia L, Howard VG, Ziani-Cherif C, Golde TE, et al. Peptide-based, irreversible inhibitors of γ-secretase activity. Biochem Biophys Res Comm 2003; 305: 529-33.
147. Ziani-Cherif C, et al. manuscript in preparation.
148. Hanessian S, Lu P-P, Sancéau J-Y, Chemla P, Gohda K, Fonne-Pfister R, et al. An enzyme-bound bisubstrate hybrid inhibitor of adenylosuccinate. Angew Chem Int Ed 1999; 38: 3160-62.
149. Carlier PR, Du Da-Ming, Han Y-F, Liu J, Perola E, Williams ID, Pang Y-P. Dimerisation of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product. Angew Chem Int Ed 2000; 39: 1775-77.
150. Srivastava S, Tewari S, Chauhan PMS, Puri SK, Bhaduri AP, Pandey VC. Synthesis of bisquinolines and their in vitro ability to produce methemoglobin I canine hemolysate. Bioorg Med Chem Lett 1999; 9: 653-58.
151. Schroeter EH, Ilagan MXG, Brunkan AL, Hecimovic S, Li Y-M, Kopan R, et al. A presenilin dimer at the core of the γ-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolyis. Proc Natl Acad Sci USA 2003; 100: 13075-80.
152. Li Y, Shearman MS, Xu M, Lai M-T, Huang Q, Castro JL, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000; 405: 689-94.
153. Rishton GM, Retz DM, Tempest PA, Novotny J, Kahn S, Treanor JJS, et al. Fenchylamine sulfonamide inhibitors of amyloid-β peptide production by the γ-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. J Med Chem 2000; 43: 2297-99.
154. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal tansduction and beta APP processing. Nature 2000; 407: 48-54.
155. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Complex N-linked glycosylated nicastrin associates with active γ-secretase and undergoes tight cellular regulation. J Biol Chem 2002; 277: 35113-17.
156. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, et al. Activity-dependant isolation of the presenilin-γ-secretase complex reveals nicastrin and a γ substrate. Proc Natl Acad Sci USA 2002; 99: 2720-25.
157. Edbauer D, Winkler E, Haass C, Steiner H. Presenilin and nicastrin regulate each other and determine amyloid β-peptide production via complex formation. Proc Natl Acad Sci USA 2002; 99: 8666-71.
158. Steiner H. Uncovering γ-secretase. Curr Alz Res 2004; 1: 1-7.
159. Chung H-M, Struhl G. Nicastrin is required for presenilin-mediated transmembrane cleavage in Drosophilia. Nat Cell Biol 2001; 3: 1129-32.
160. Lopez-Schier H, Johnston DS. Drosophilia nicastrin is essential for the intramembranous cleavage of Notch. Dev Cell 2002; 2: 79-89.
161. Hu Y, Ye Y, Fortini ME. Nicastrin is required for γ-secretase cle2vage of the Drosophilia Notch receptor. Dev Cell 2002; 2:69-78.
162. Li T, Ma G, Cai H, PriceL, Wong PC. Nicastrin is required for assembly of presenilin/γ-secretase complexes to mediate Notch signaling and for processing and trafficking of β-amyloid precursor protein in mammals. J Neurosci 2003; 23: 3272-77.
163. Li J, Fici GJ, Mao C-A, Myers RL, Shuang R, Donoho GP, et al. Positive and negative regulation of the γ-secretase activity by nicastrin in murine model. J Biol Chem 2003; 278: 33445-49.
164. Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA 2002; 99: 775-79.
165. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. Aph-1 and Pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev Cell 2002; 3: 85-97.
166. Murphy MP, Das P, Nyborg AC, Rochette MJ, Dodson MW, Loosbrock NM, et al. Overexpression of nicastrin increases Aβ production. FASEB J 2003; 17: 1138-40.
167. Fortna RR, Crystal AS, Morais VA, Pijak DS, Lee VM, Doms RW. Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the γ-secretase complex. J Biol Chem 2003; 279: 3685-93.
168. Lee SF, Shah S, Li H, Yu C, Han W, Yu G. Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-β precursor protein and Notch. J Biol Chem 2002; 277: 45013-19.
169. Crystal AS, Morais VA, Pierson TC, Pijak DS, Carlin D, Lee VM, et al. Membrane topology of γ-secretase component PEN-2. J Biol Chem 2003; 278: 20117-23.
170. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of γ-secretase activity. Nat Cell Biol 2003; 5: 486-88.
171. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1 and Pen-2. Proc Natl Acad Sci USA 2003; 100: 6382-87.
172. De Strooper B. Aph-1, Pen-2, and Nicastrin with presenilin generate an active γ-secretase complex. Neuron 2003; 38: 9-12.
173. Campbell WA, Reed MLO, Strahle J, Wolfe MS, Xia W. Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from γ-secretase. J Neurochem 2003; 85: 1563-74.
174. Serneels L, Dejaegere T, Craessaerts K, Horré K, Jorissen E, Tousseyn T, et al. Differential contribution of the three Aph1 genes to γ-secretase activity in vivo. Proc Natl Acad Sci USA 2005; 102: 1719-24.
175. Massey LK, Mah AL, Monteiro MJ. Ubiquilin regulates presenilin endoproteolysis and modulates γ-secretase components, Pen-2 and Nicastrin. Biochem J 2005; 391(Pt 3): 513-25.
176. Das I, Craig C, Funahashi Y, Jung K-M, Kim T-W, Byers R, et al. Notch oncoproteins depends on γ-secretase/presenilin activity for processing and function. J Biol Chem 2004; 279: 30771-80.
177. Marjaux E, De Strooper B. γ-Secretase inhibitors: still in the running as Alzheimer's therapeutics. Drug Discov Today Ther Strategies 2004; 1: 1-6.
178. Zhou S, Zhou H, Walian PJ, Jap BK. CD147 is a regulatory subunit of the γ-secretase complex in Alzheimer's disease amyloid β-peptide production. Proc Natl Acad Sci USA 2005; 102: 7499-504.
179. Pollack SJ, Lewis H. γ-Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Op Invest Drugs 2005; 6: 35-47.
180. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005; 1-12.
181. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/ progenitor cells. Breast Cancer Res 2004; 6: 605-15.
182. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J Neurosci 2003; 23: 5531-35.
183. Paris D, Quadros A, Patel N, DelleDone A, Humphrey J, Mullan M. Inhibition of angiogenesis and tumor growth by β and γ-secretase inhibitors. Eur J Pharm 2005; 514: 1-15.
184. Paterson D, Ognjenovic M. American Chemical Society-228th National Meeting. Gamma-secretase inhibitors. 22-26 August 2004, Philadelphia, PA, USA. IDrugs 2004; 7: 895-7. ( PMID: 15478008).
185. Tomita T, Iwatsubo T. The inhibition of γ-secretase as a therapeutic approach to Alzheimer's disease. Drug News Perspect 2004; 17: 321.
186. Beher D, Shearman MS. γ-Secretase inhibition. Biochem Soc Trans 2002; 30: 534-37.
187. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-85.
188. Golde TE, Younkin SG. Presenilins as therapeutic targets for the treatment of Alzheimer's disease. Trends Mol Med 2001; 7: 264-69.
189. Petit A, Bihel F, Alves da Costa C, Pourquié O, Checler F, Kraus JL. New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage. Nat Cell Biol 2001; 3: 507-11.
190. Bihel F, Quéléver G, Lelouard H, Petit A, Alvès da Costa C, Kraus JL, et al. Synthesis of new 3-alkoxy-7-amino-4-chloro-isocoumarin derivatives as new β-amyloid peptide production inhibitors and their activities on various classes of protease. Bioorg Med Chem 2003; 11: 3141-52.
191. Kornilova AY, Das C, Wolfe MS. Differential effects of inhibitors on the γ-secretase complex. J Biol Chem 2003; 278: 16470-73.
192. See www.clinicaltrials.gov for up-to-date information on which trials are enrolling and whom to contact locally.
193. Doerfler P, Shearman MS, Perlmutter RM. Presenilin-dependent γ-secretase activity modulates thymocyte development. Proc Natl Acad Sci USA 2001; 98: 9312-17.
194. Beher D, Wrigley JDJ, Owens AP, Shearman MS. Generation of C-terminally truncated amyloid-β peptides is dependent on γ-secretase activity. J Neurochem 2002; 82: 1-14.
195. Lewis, HD, Pérez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, Shearman MS. Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and β-APP cleavages. Biochemistry 2003; 42: 7580-86.
196. Nadin A, Owens AP, Castro JL, Harrison T, Shearman MS. Synthesis and γ-secretase activity of APP substrate-based hydroxyethylene dipeptide isosteres. Bioorg Med Chem Lett 2003; 13: 37-41.
197. Churcher I, Ashton K, Butcher JW, Clarke EE, Harrison T, Lewis HD, et al. A new series of potent benzodiazepine γ-secretase inhibitors. Bioorg Med Chem Lett 2003; 13: 179-83.
198. Churcher I, Williams S, Kerrad S, Harrison T, Castro JL, Shearman MS, et al. Design and synthesis of highly potent benzodiazepine γ-secretase inhibitors: preparation of (2S, 3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)- 1-methyl-2-oxo-5-phe-nyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl) butyramide by use of an asymmetric Ireland-Claisen rearrangement. J Med Chem 2003; 46: 2275-78.
199. Owens AP, Nadin A, Talbot AC, Clarke EE, Harrison T, Lewis HD, et al. High affinity, bioavailable 3-amino-1,4-benzodiazepinebased γ-secretase inhibitors. Bioorg Med Chem Lett 2003; 13: 4143-45.
200. Lewis SJ, Smith AL, Neduvelil JG, Stevenson GI, Lindon MJ, Jones AB, et al. A novel series of potent γ-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core. Bioorg Med Chem Lett 2005; 15: 373-78.
201. Teall M, Oakley P, Harrison T, Shaw D, Kay E, Elliott J, et al. Aryl sulfones: a new class of γ-secretase inhibitors. Bioorg Med Chem Lett 2005; 15: 2685-88.
202. Grimwood S, Hogg J, Jay MT, Lad AM, Lee V, Murray F, et al. Determination of guinea-pig cortical γ-secretase activity ex-vivo following the sytemic administration of a γ-secretase inhibitor. Neuropharm 2005; 48: 1002.
203. 2-[(2S)-2-(3,5-Difluorophenyl)- 2-hydroxyethanol]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]] azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 2005; 313: 902-08.
204. Harrison T, Churcher I, Beher D. Gamma-secretase as a target for drug intervention in Alzheimer's disease. Curr Opin Drug Dis Dev 2004; 7: 709-19.
205. Weihofen A, Lemberg MK, Ploegh HL, Bogyo M, Martoglio B. Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor. J Biol Chem 2000; 275: 30951-56.
206. Weihofen A, Lemberg MK, Friedmann E, Rueeger H, Schmitz A, Martoglio B, et al. Targeting presenilin-type aspartic protease signal peptide peptidase with γ-secretase inhibitors. J Biol Chem 2003; 278: 16528-33.
207. Esler WP, Das C, Wolfe MS. Probing pockets S2-S4′ of the γ-secretase active site with (hydroxyethyl)urea peptidomimetics. Bioorg Med Chem Lett 2004; 14: 1935-38.
208. Bakshi P, Wolfe MS. Stereochemical analysis of (hydroxyethyl)urea peptidomimetic inhibitors of γ-secretase. J Med Chem 2004; 47: 6485-89.
209. Das C, Berezovska O, Diehl TS, Genet C, Buldyrev I, Tsai J-Y, et al. Designed helical peptides inhibit an intramembrane protease. J Am Chem Soc 2003; 125: 11794-95.
210. Bihel F, Das C, Bowman MJ, Wolfe MS. Discovery of a subnanomolar helical D-tridecapeptide inhibitor of γ-secretase. J Med Chem 2004; 47: 3931-33.
211. Bakshi P, Liao YF, Gao J, Ni J, Stein R, Yeh LA, Wolfe MS. A high-throughput screen to identify inhibitors of amyloid betaprotein precursor processing. J Biomol Screen 2005; 10: 1-12.
212. Garofalo AW, Wone DWG, Phuc A, Audia JE, Bales CA, Dovey HF, et al. A series of C-terminal amino alcohol dipeptide Aβ inhibitors. Bioorg Med Chem Lett 2002; 12: 3051-53.
213. Wallace OB, Smith DW, Deshpande MS, Polson C, Felsenstein KM. Inhibitors of Aβ production: solid-phase synthesis and SAR of α-hydroxycarbonyl derivatives. Bioorg Med Chem Lett 2003; 13: 1203-06.
214. Chun J, Yin YI, Yang G, Tarassishin L, Li YM. Stereoselective synthesis of photoactive peptidomimetic γ-secretase inhibitors. J Org Chem 2004; 69: 7344-47.
215. Smith DW, Munoz B, Srinivasan K, Bergstrom CP, Chaturvedula PV, Deshpande MS, et al. Preparation of sulfonamide derivatives as amyloid production inhibitors useful in treating or preventing diseases related to. WO 0050391, 2000. Chem Abstr 2000; 133: 207678.
216. Gundersen E, Fan K, Haas K, Huryn D, Jacobsen JS, Kreft A, et al. Molecular-modeling based design, synthesis, and activity of substituted piperidines as γ-secretase inhibitors. Bioorg Med Chem Lett 2005; 15: 1891-94.
217. Laras Y, Quélever G, Garino C, Pietrancosta N, Sheha M, Kraus JL, et al. Substituted thiazolamide coupled to a redox delivery system: a new γ-secretase inhibitor with enhanced pharmacokinetic profile. Org Biomol Chem 2005; 3: 612-18.
218. Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, et al. Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharm 2005; 69: 689-98.
219. In T'veld BA, Ruitenberg A, Hofman A, Launer LJ, Van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21.
220. Sagi SA, Weggen S, Ericksen J, Golde TE, Koo EH. The Noncyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of ΚB kinase, and NFΚB, do not reduce amyloid β42 production. J Biol Chem 2003; 278: 31825-30.
221. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activty. Nature 2001; 414: 212-16.
222. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDS and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J Clin Invest 2003; 112: 440-49.
223. Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, et al. Sulindac sulfide is a noncompetitive γ-secretase inhibitor that preferentially reduces Ab42 generation. J Biol Chem 2003; 278: 18664-70.
224. Sastre M, Dewatcher I, Landreth GE, Wilson TM, Klockgether T, Van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J Neurosci 2003 23: 9796-804.
225. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity. J Biol Chem 2003; 278: 31831-37.
226. Beher D, Clarke EE, Wrigley JDJ, Martin ACL, Nadin A, Churcher I, Shearman MS. Selected non-Steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel Site. Evidence for an allosteric mechanism. J Biol Chem 2004; 279: 43419-26.
227. 1-42 secretion. J Med Chem 2005; 48: 5705-20.
228. Imbimbo BP. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Invest Drugs 2004; 13: 1-13.
229. Churcher I, Beher D. Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. Curr Pharm Des 2005; 11(26): 3363-82.
230. El Mouedden M, Vandermeeren M, Meert T, Mercken M. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors. Curr Pharm Des 2006; 12(6): 671-6.
231. Tomita T, Iwatsubo T. gamma-secretase as a therapeutic target for treatment of Alzheimer's disease. Curr Pharm Des 2006; 12(6): 661-70.